IPA — Immunoprecise Antibodies Income Statement
0.000.00%
- $21.97m
- $27.94m
- CA$20.67m
- 37
- 66
- 24
- 38
Annual income statement for Immunoprecise Antibodies, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10.9 | 14.1 | 17.9 | 19.4 | 20.7 |
Cost of Revenue | |||||
Gross Profit | 5.29 | 8.03 | 11.5 | 11 | 11.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Operating Interest Expense / Income | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 18.1 | 19.5 | 23 | 36 | 49.2 |
Operating Profit | -7.22 | -5.4 | -5.08 | -16.7 | -28.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.61 | -5.29 | -6 | -15.8 | -27.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.62 | -4.95 | -7.34 | -16.7 | -26.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.62 | -4.95 | -7.34 | -16.7 | -26.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.62 | -4.95 | -7.34 | -16.7 | -26.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.571 | -0.323 | -0.545 | -0.846 | -1.07 |